CBIO Q4 2020 Earnings — Crescent Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

CBIOCrescent Biopharma, Inc.

$337M

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$162,935

Gross Profit

$162,935100.0% margin

Operating Income

-$16M-9554.9% margin

Net Income

-$16M-9551.5% margin

EPS (Diluted)

$-0.32

QoQ Revenue Growth

-83.7%

Cash Flow

Operating Cash Flow

-$10M

Free Cash Flow

-$10M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$143M

Total Liabilities

$15M

Stockholders' Equity

$128M

Cash & Equivalents

$137M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$162,935	$0	—
Gross Profit	$162,935	-$228,312	+171.4%
Operating Income	-$16M	-$15M	-1.5%
Net Income	-$16M	-$15M	-5.7%